and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4 and R5 have any of the meanings defined herein, for use in the treatment of Huntington's disease."/>
公开/公告号EP3683220A1
专利类型
公开/公告日2020-07-22
原文格式PDF
申请/专利权人 ASTRAZENECA AB;
申请/专利号EP20200156172
申请日2016-09-15
分类号C07D471/04;A61K31/4745;A61P25/28;A61P35;
国家 EP
入库时间 2022-08-21 11:39:52